Search clinical trials for: Integrase

Total 571 results

Emory University
National Institute of Allergy and Infectious Diseases (NIAID)

Terminated

Dolutegravir in Reservoirs

HIV

United States
University of Liege

Completed

Effect of Dolutegravir Intensification on HIV-1 Reservoirs (EDIT)

HIV-1-infection

Belgium
NEAT ID Foundation
ViiV Healthcare

Completed

An Open-Label, Multi-Centre, Randomised, Switch Study to Evaluate the Virological Efficacy Over 96 Weeks Of 2-Drug Therapy With DTG/RPV FDC in Antiretroviral Treatment-Experienced HIV-1 Infected Subjects Virologically Suppressed With NNRTIs Resistance Mutation K103N (WISARD)

HIV-1-infection

Spain, Belgium, France, Germany, Italy, United Kingdom
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Efficacy and Safety of Dolutegravir-Containing Versus Efavirenz-Containing Antiretroviral Therapy Regimens in HIV-1-Infected Pregnant Women and Their Infants (VESTED)

HIV Infections

United States, South Africa, Thailand, Botswana, Brazil, Tanzania, Zimbabwe, India, Uganda
University of Maryland, Baltimore
Merck Sharp & Dohme LLC

Completed

R5 Integrase Study in HIV-1 Naive Patients

HIV Infections

United States
University of Cape Town
Wellcome Trust; Médecins Sans Frontières, Belgium

Completed

Tenofovir-lamivudine-dolutegravir Combination as Second-line ART: a Randomised Controlled Trial (ARTIST)

HIV Infections

South Africa
Novartis Pharmaceuticals
Medicines for Malaria Venture

Completed

Drug-drug Interaction Study of Ganaplacide and Lumefantrine With Midazolam, Repaglinide, Dextromethorphan, Metformin, Rosuvastatin and Dolutegravir

Malaria

United Kingdom
Johns Hopkins University
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Rapid HIV Treatment Initiation, Access and Engagement in Care

Human Immunodeficiency Virus

United States
Fenway Community Health
Merck Sharp & Dohme LLC

Completed

HIV Non Occupational Post-Exposure Prophylaxis (PEP)

HIV Infections

United States
ViiV Healthcare
GlaxoSmithKline

Completed

ING200336, Pharmacokinetic and Safety Study in Pregnant Women With Human Immuno Virus Infection

HIV Infections | Arthralgia | Infection, Human Immunodeficiency Virus

Spain, Russian Federation
Michael Hoelscher
Radboud University Medical Center; German Federal Ministry of Education and... and other collaborators

Completed

BTZ-043 - Multiple Ascending Dose (MAD) to Evaluate Safety, Tolerability and Early Bactericidal Activity (EBA)

Pulmonary Tuberculoses | Other Specified Pulmonary Tuberculosis

South Africa
National Institute of Allergy and Infectious Diseases...
Eunice Kennedy Shriver National Institute of Child Health and Human Development...

Completed

Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy

HIV Infections

United States, Puerto Rico, Thailand, Botswana, Argentina, Brazil, Tanzania, South Africa
University of Liege

Active, not recruiting

Impact of DOlutegravir+Lamivudine Simplification on HIV-1 Reservoirs (IDOLTIB)

HIV Infections

Belgium
National Institute of Allergy and Infectious Diseases...

Completed

Integrase and Maraviroc Intensification in Neurocognitive Dysfunction (InMIND)

HIV Infections

United States, Puerto Rico, Thailand, South Africa, Brazil
Pedro Cahn
ViiV Healthcare

Withdrawn

Dolutegravir-Lamivudine as Dual Therapy in naïve HIV-Infected Patients With Documented M184V Mutation:A Pilot Study (PADDLE184V)

HIV-1 Infection

Argentina
Fundación FLS de Lucha Contra el Sida, las Enfermedades...
ViiV Healthcare

Completed

EFFICACY AND SAFETY OF A SIMPLIFICATION STRATEGY BASED ON DOLUTEGRAVIR AND DARUNAVIR / COBICISTAT VS OPTIMIZED TREATMENT IN SUPPRESSED HIV-1-INFECTED PATIENTS CARRYING ARCHIVED MULTIDRUG RESISTANCE MUTATIONS

HIV-1 Infection

Spain
Mylan Inc.
ViiV Healthcare

Completed

Abacavir, Dolutegravir and Lamivudine Dispersible Tablets (60 mg/5 mg/30 mg)

HIV-1-infection

Canada
Sabyasachi Sen

Completed

Effect on HIV Medications on EPC Cells

AIDS

United States
ViiV Healthcare
GlaxoSmithKline; Shionogi

Completed

A Study of GSK1349572 Versus Raltegravir (RAL) With Investigator Selected Background Regimen in Antiretroviral-Experienced, Integrase Inhibitor-Naive Adults (SAILING)

HIV Infections | Infection, Human Immunodeficiency Virus

United States, France, Netherlands, Spain, Taiwan, Australia, Belgium, Russian Federation, Canada, United Kingdom, Mexico, Italy, South Africa, Romania, Argentina, Hungary, Poland, Chile, Greece, Brazil
Gilead Sciences

Completed

Study to Evaluate the Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in Human Immunodeficiency Virus (HIV-1) Infected, Antiretroviral Treatment-Naive Adults

HIV-1 Infection

Spain, United States, Italy, Germany, United Kingdom, France, Australia, Puerto Rico, Canada, Belgium, Dominican Republic
Rhonda Brand
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Development of a Urine-Based Point-of-Care Test for Adherence to Antiretroviral Drugs (APTAMER)

HIV | Medication Adherence

United States
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Safety, Tolerability, and Pharmacokinetics of Bedaquiline and Delamanid, Alone and in Combination, For Drug-Resistant Pulmonary Tuberculosis

HIV Infections | Tuberculosis

Peru, South Africa
University of Nairobi
ViiV Healthcare

Completed

Second-line Switch to Dolutegravir Study (2SD)

HIV-1-infection

Kenya
Viriom

Completed

Study to Evaluate the Safety and PK of Elpida® in Healthy Subjects and Patients With Hepatic Impairment and to Assess the Impact of Food Intake and Drug-Drug Interactions With Other Antiviral Drugs

Hepatic Impairment | HIV-1-infection

Russian Federation
Gilead Sciences

Completed

Switching to a Fixed Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Adults Who Are Virologically Suppressed

HIV-1-infection

United States, Puerto Rico, France, Germany, Austria, Canada
ANRS, Emerging Infectious Diseases
Institut National de la Santé Et de la Recherche Médicale, France

Completed

National Multicenter Trial Evaluating Two Treatments in Patients With Primary Human Immunodeficiency Virus (HIV-1) Infection (OPTIPRIM-2)

HIV-1 Infection

France
Midland Research Group, Inc.
Janssen Pharmaceuticals

Terminated

Integrase Regimen Switch to Symtuza to Increase Tolerability/Adherence (SYMita) (SymITA)

Human Immunodeficiency Virus

United States
University of North Carolina, Chapel Hill
ViiV Healthcare

Completed

Safety and Efficacy of Fixed Dose Combination Dolutegravir/Abacavir/Lamivudine FDC Initiated During Acute HIV Infection (PHI-05)

HIV | Acute HIV Infection

United States
Johns Hopkins University
Gilead Sciences

Completed

Analysis of Crushed and Whole Tablet Genvoya

Healthy Volunteers

United States
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Safety and Pharmacokinetics of Raltegravir in Infants

HIV Infections

United States, South Africa, Brazil, Tanzania, Thailand
National Institute of Allergy and Infectious Diseases...

Completed

Safety, Tolerance and Pharmacokinetics of Raltegravir-Containing Antiretroviral Therapy in Infants, Children Infected With HIV and TB

HIV Infections | Tuberculosis

South Africa
National Institute of Allergy and Infectious Diseases...

Completed

Safety and Pharmacokinetics of Raltegravir in HIV-1-Exposed Newborn Infants at Risk of Acquiring HIV-1 Infection

HIV Infections

United States, Thailand, Puerto Rico, Brazil, South Africa
National Institute of Allergy and Infectious Diseases...

Completed

Effect of Addition of Raltegravir (MK-0518) to PI- or NNRTI-Based ART Regimens in HIV Infected Subjects With Undetectable Viral Load

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...
AIDS Clinical Trials Group

Completed

Optimizing Treatment for Treatment-Experienced, HIV-Infected People

HIV Infections

United States, Puerto Rico
National Institute of Allergy and Infectious Diseases...
Eunice Kennedy Shriver National Institute of Child Health and Human Development...

Completed

Safety and Pharmacokinetics (PK) of Raltegravir in HIV (Human Immunodeficiency Virus)-Infected Children and Adolescents

HIV Infections

United States, Puerto Rico, South Africa, Argentina, Brazil, Botswana
Shionogi

Completed

Evaluation of Safety, Tolerability, Pharmacokinetics, Drug-Drug and Food Interactions of Single and Multiple Doses of S-648414 in Healthy Adults

Healthy Volunteer

United States, Japan
National Institute of Allergy and Infectious Diseases...
Adult AIDS Clinical Trials Group

Completed

Study of Viral Load Decay Rates in HIV Infected Participants Starting Treatment With Raltegravir (RAL) and Emtricitabine/Tenofovir Disoproxil Fumarate (TDF)

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

Intensive Viral Dynamics Substudy of A5248

HIV Infections | Treatment Naive

United States
ViiV Healthcare

Completed

Rapid Test and Treat Dolutegravir Plus Lamivudine Study in Newly Diagnosed Human Immunodeficiency Virus (HIV)-1 Infected Adults

HIV Infections

United States
University of Maryland, Baltimore

Completed

Switch to Maraviroc + Integrase Inhibitor

HIV

United States
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Safety, Tolerability, and Pharmacokinetics of an Investigational, Injectable HIV Medicine (GSK1265744) in HIV-Uninfected Adults

HIV Infections

United States, Malawi, Brazil, South Africa
Helsinki University Central Hospital
Merck Sharp & Dohme LLC

Completed

Effect on Liver Fat and Metabolic Parameters When Switching a Protease Inhibitor or Efavirenz to Raltegravir (OBERAL)

Fatty Liver | Metabolic Syndrome | HIV Seropositivity

Finland
ANRS, Emerging Infectious Diseases
UNITAID; Institut de Recherche pour le Developpement

Completed

Efficacy and Safety of a Dolutegravir-based Regimen for the Initial Management of HIV Infected Adults in Resource-limited Settings (NAMSAL)

HIV-1 Infection

Cameroon
Emory University
Centers for Disease Control and Prevention

Completed

Body Compartment Pharmacokinetics of Anti-retroviral Agents That May be Considered for Future On-demand Peri-exposure HIV Prophylaxis Regimens

HIV/AIDS

United States
University of Hawaii
Oxford University Clinical Research Unit, Vietnam; Hospital for Tropical Diseases... and other collaborators

Completed

Hepatic Safety of Raltegravir Versus Efavirenz as HIV Therapy for Patients With HIV and HCV Coinfection

HIV Infection | Hepatitis C, Chronic

Vietnam
AIDS Clinical Trials Group
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Study of Options for Second-Line Effective Combination Therapy (SELECT) (SELECT)

HIV-1 Infection

Peru, Kenya, Malawi, Brazil, South Africa, Zimbabwe, India, Thailand, Tanzania
Stanford University
University of Colorado, Denver; Janssen Scientific Affairs, LLC

Withdrawn

Darunavir/Cobicistat and Dolutegravir to Maintain Virologic Suppression and Reduce NRTI-associated Toxicity (TMC114HIV2030)

HIV/AIDS

United States
University Hospital, Montpellier
Institute of Human Genetics, France

Completed

Testing the Effect of Raltegravir on Persistent de Novo HIV Infection in Virologic Responders to Antiretroviral Therapy (RALNOVO)

HIV-1 Infection

France
Radboud University Medical Center
University Medical Center Groningen; Erasmus Medical Center; Leiden University...

Withdrawn

Pharmacokinetics of Single-dose Dolutegravir in HIV-seronegative Subjects With Severe Hepatic Impairment Compared to Matched Controls. (POLO)

Hepatic Impairment | HIV-1-infection
ViiV Healthcare

Available

GSK1265744 (Cabotegravir, CAB) for Named Patient/Compassionate Use in HIV

Infection, Human Immunodeficiency Virus

Search clinical trials for: Integrase

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Dominican Republic

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations